one major class of these molecularly targeted agents, and the first of them, STI571 (Gleevec, imatinib mesylate) and ZD1839 (Iressa, gefitinib), have already entered the market [4, 5]. STI571 is a potent inhibitor of the tyrosine kinases Abl, c-kit, and platelet-derived growth factor 
To address these important questions, we introduced equivalent amino acid substitutions into three other protein tyrosine kinases. The sensitivities of the mutant kinases were determined for a selection of structurally distinct inhibitors. With one important exception, all of the inhibitor classes tested were prone to a conserved mechanism of molecular resistance formation. In addition, the drug-resistant kinase mutants provided useful tools for chemical-genetic analysis of cellular signaling.
Results

Protein Kinase Alignment and Inhibitor Selection
The side chain of Thr-315 in the Abl tyrosine kinase controls the access to a hydrophobic pocket at the ATP binding site [7, 9] . This cavity accommodates moieties of ATP-competitive inhibitors, such as STI571 and PD180970, but no functional groups of ATP itself [9, 13]. Thus, replacement of Thr-315 by larger residues interferes with inhibitor binding, while leaving the kinase activity intact. The smaller amino acids threonine or valine are present at the corresponding site in a subset of all human kinases, and an alignment of those belonging to this group and relevant for this study is shown in Figure  1A . For a comprehensive analysis of this structural feature with respect to resistance formation, we selected a variety of inhibitors belonging to distinct compound classes ( Figure 1B) . The EGFR inhibitor ZD1839 (Iressa, gefitinib) has recently received FDA approval for thirdline treatment of non-small cell lung cancer [5, 14] . The pyrazolopyrimidine PP1 was originally described as a Src family kinase-specific inhibitor but was later found to block ␤PDGFR activity with similar potency [15] . The 2-phenylaminopyrimidine STI571 is a potent inhibitor of the tyrosine kinases Abl, c-kit, and PDGFR [6]. The quinoxaline compound AG1296 is used as a selective resistance formation to ZD1839, we transiently exand vascular endothelial growth factor receptor-2) [18] . pressed both wild-type EGFR and the EGFR-T766M muFinally, the indolinones SU6656 and SU4984 have been tant in CHO-K1 cells, which lack endogenous EGFR described as inhibitors of Src family kinases and FGFR1, expression. As shown in Figure 2 , pretreatment of cells respectively [19, 20] . with 25 nM ZD1839 strongly suppressed EGF-stimulated tyrosine phosphorylation of the wild-type RTK, whereas, in stark contrast, 100-fold higher concentraSubstitution of Methionine for Thr-766 Desensitizes the EGFR to the Anticancer Drug ZD1839 tions were without effect on the EGFR-T766M mutant. Thus, molecular resistance formation of the EGFR is also In a previous report, we demonstrated that replacing Thr-766 with methionine dramatically reduced the sensiobserved for ZD1839 upon introduction of the equivalent nucleotide change that substitutes Thr-315 with isoleutivity of the EGFR to inhibition by the specific 4-anilinoquinazoline PD153035 [12] . Importantly, structurally cine in Bcr-Abl from STI571-insensitive CML patients. Moreover, in case of the EGFR, the C to T transition related quinazolines have been developed for targetselective inhibition of the EGFR in human cancer pareplacing Thr-766 with methionine (ACG to ATG) would occur within a CpG dinucleotide sequence. Notably, due tients, and ZD1839 (Iressa, gefitinib) is the most ad- to their susceptibility to methylation-deamination reacconversion leads to dramatic resistance formation of the ␤PDGFR. This finding extends previous data from tions, these sites are mutational hotspots within the human genome and therefore account for the most fremutational analysis of this position in the ␤PDGFR. Figure 3D , both wild-type and mutant ␤PDGFR were inhibited by this compound resistance formation in these ␤PDGFR-driven malignancies might occur through similar mechanisms as demonwith an comparable IC 50 of about 0.5 to 1 M in intact cells. strated for Bcr-Abl in late-phase CML patients. Here, we focus on the single C to T nucleotide change known to confer STI571-resistance to Bcr-Abl by replacing Thr-315
Analysis of Resistance Formation for Src and FGFR1 Tyrosine Kinase Mutants with isoleucine. Analogous mutation of the equivalent codon 681 of the ␤PDGFR generated the ␤PDGFR-T681I
The ␤PDGFR mutant experiments established Thr-681 as a structural determinant critical for sensitivity to sevmutant possessing the same amino acid substitution. We then transiently expressed both wild-type receptor eral distinct inhibitor scaffolds. We next asked whether these findings can be extended to other tyrosine kinase and the ␤PDGFR-T681I mutant in COS-7 cells and measured the effect of STI571 treatment on PDGF-stimutargets. For this purpose, we replaced the equivalent amino acids Thr-341 in the cytoplasmic Src tyrosine lated cellular RTK activity by immunoblot analysis of ␤PDGFR autophosphorylation on intracellular tyrosine kinase and Val-561 in the FGFR1 RTK with larger methionine residues. To activate Src tyrosine kinase, the carresidues. As shown in Figure 3A tified in recent years. These reagents are useful for both signal transduction research and therapeutic inmutations can be divided into two groups: some substitutions of general relevance for protein kinase inhibition, tervention in various diseases. The inhibition of some protein kinases, such as p38, the EGFR, or Bcr-Abl, such as T315I, which directly interfere with inhibitor interaction, and the larger group of those, which are speby target-selective, ATP-competitive compounds was described to depend on the presence of a small threocific for STI571 due to the special conformational state of its targets required for efficient binding. These considnine residue at a specific site near the nucleotide binding pocket. Substitutions with larger residues renerations imply that STI571 would be particularly vulnerable to resistance formation and that this risk can be dered mutant protein kinases insensitive to selective inhibitors without abrogating kinase activity, and this minimized with target conformation-independent inhibitors. For these compounds, only the direct interaction type of mutation was also prominent in leukemia patients who had developed resistance to treatment with sites, such as the residue corresponding to Thr-315 of Abl and Thr-766 of the EGFR, might be critical for protein the BCR-ABL kinase inhibitor STI571 (Gleevec) [7, 11, 12] . We show a similar mode of cellular resistance kinase inhibition. We have therefore focused on the relevance of this structural feature in the present study [7, formation for the EGFR-selective drug ZD1839 (Iressa). targeting both Src tyrosine kinase and its negative regulator CSK, the expression of a drug-insensitive
